TW200523249A - Novel heteroaryl derivative - Google Patents

Novel heteroaryl derivative Download PDF

Info

Publication number
TW200523249A
TW200523249A TW093121149A TW93121149A TW200523249A TW 200523249 A TW200523249 A TW 200523249A TW 093121149 A TW093121149 A TW 093121149A TW 93121149 A TW93121149 A TW 93121149A TW 200523249 A TW200523249 A TW 200523249A
Authority
TW
Taiwan
Prior art keywords
group
substituted
heteroaryl
mmol
ring
Prior art date
Application number
TW093121149A
Other languages
English (en)
Chinese (zh)
Other versions
TWI331142B (https=
Inventor
Ken-Ichi Watanabe
Katsunori Maruta
Kantaro Ushiroda
Ryu Nagata
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Publication of TW200523249A publication Critical patent/TW200523249A/zh
Application granted granted Critical
Publication of TWI331142B publication Critical patent/TWI331142B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333Radicals substituted by oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
TW093121149A 2003-07-15 2004-07-15 Novel heteroaryl derivative TW200523249A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003274684 2003-07-15

Publications (2)

Publication Number Publication Date
TW200523249A true TW200523249A (en) 2005-07-16
TWI331142B TWI331142B (https=) 2010-10-01

Family

ID=34113749

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093121149A TW200523249A (en) 2003-07-15 2004-07-15 Novel heteroaryl derivative

Country Status (11)

Country Link
US (2) US7425642B2 (https=)
EP (1) EP1647546B1 (https=)
JP (2) JP4820169B2 (https=)
KR (1) KR101086654B1 (https=)
CN (1) CN100516041C (https=)
AT (1) ATE556051T1 (https=)
CA (1) CA2531064C (https=)
ES (1) ES2383895T3 (https=)
MX (1) MXPA06000539A (https=)
TW (1) TW200523249A (https=)
WO (1) WO2005012245A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006075638A1 (ja) * 2005-01-14 2006-07-20 Dainippon Sumitomo Pharma Co., Ltd. 新規ヘテロアリール誘導体
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
WO2008157537A2 (en) * 2007-06-19 2008-12-24 Ironwood Pharmaceuticals, Inc Compositions and methods of use for treating or preventing lipid related disorders
CN102202662A (zh) * 2008-10-31 2011-09-28 大日本住友制药株式会社 抗糖尿病剂
US20120010264A1 (en) * 2009-03-26 2012-01-12 Dainippon Sumitomo Pharma Co., Ltd. Novel medicament for treating cognitive impairment
WO2011002012A1 (ja) * 2009-07-01 2011-01-06 大日本住友製薬株式会社 Sglt1阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
HUE044867T2 (hu) 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteosztázis szabályzók
US10266490B2 (en) * 2012-03-16 2019-04-23 Georgetown University Radioprotector compounds
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2752361A1 (de) * 1977-11-24 1979-06-07 Troponwerke Gmbh & Co Kg Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0973778A1 (en) * 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
EP1284260A4 (en) 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd TYROSIN PHOSPHATASE INHIBITORS
JP2002121186A (ja) * 2000-05-22 2002-04-23 Takeda Chem Ind Ltd チロシンホスファターゼ阻害剤
ATE423120T1 (de) * 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
EP1386913B1 (en) * 2001-04-19 2008-07-16 Dainippon Sumitomo Pharma Co., Ltd. Pyrrole derivative
JP2003171275A (ja) 2001-12-11 2003-06-17 Sumitomo Pharmaceut Co Ltd PPARδアゴニスト
JPWO2004048341A1 (ja) 2002-11-28 2006-03-23 住友製薬株式会社 新規ヘテロアリール誘導体

Also Published As

Publication number Publication date
CN1849303A (zh) 2006-10-18
JP2011251974A (ja) 2011-12-15
TWI331142B (https=) 2010-10-01
KR20060040681A (ko) 2006-05-10
EP1647546A1 (en) 2006-04-19
US20060194857A1 (en) 2006-08-31
US7425642B2 (en) 2008-09-16
US20080306275A1 (en) 2008-12-11
WO2005012245A1 (ja) 2005-02-10
JPWO2005012245A1 (ja) 2006-09-14
CN100516041C (zh) 2009-07-22
CA2531064A1 (en) 2005-02-10
MXPA06000539A (es) 2006-03-30
JP4820169B2 (ja) 2011-11-24
CA2531064C (en) 2012-05-22
ATE556051T1 (de) 2012-05-15
EP1647546A4 (en) 2008-07-23
KR101086654B1 (ko) 2011-11-24
ES2383895T3 (es) 2012-06-27
HK1087409A1 (en) 2006-10-13
EP1647546B1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
CN104352492B (zh) 以芳基磺酰基衍生物作为有效成分的长链脂肪酸延长酶抑制剂
CN105121423B (zh) 3‑(4‑(苄氧基)苯基)己‑4‑炔酸衍生物、其制备方法、和包括其作为有效成分的用于预防和治疗代谢性疾病的药物组合物
JP2024501641A (ja) 置換大環状化合物及び関連する治療方法
TW201006812A (en) Trisubstituted pyrazoles
TW200914449A (en) Organic compounds
KR102498741B1 (ko) 질환 치료용 이-치환된 피라졸 화합물
KR101819639B1 (ko) 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물
JP2011251974A (ja) 新規ヘテロアリール誘導体
US11046683B2 (en) Activator of TREK (TWIK RElated K+ channels) channels
TW201043603A (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
TW201736362A (zh) 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
CA2922933A1 (en) 2,8-diazaspiro[4.5]decane and 3,9-dispiro[5.5]undecane derivates and pharmaceutical compositions thereof useful as tryptophan hydroxylase inhibitors
CN105246896A (zh) 吡唑并吡咯烷-4-酮衍生物及其在治疗疾病中的用途
US20160355475A1 (en) Novel indole derivative compound and pharmaceutical composition comprising the same
US20240368113A1 (en) Amide compound and use thereof
TW202216684A (zh) 用於抑制與降解雄激素受體的化合物、醫藥組合物及其應用
EP3412664B1 (en) Heterocyclic sulfonamide derivative and medicine containing same
CN114008040A (zh) 用于调节fxr的化合物
WO2006075638A1 (ja) 新規ヘテロアリール誘導体
JP2013100235A (ja) 新規インドール誘導体
CN117143039B (zh) 一种苯并五元氮环类化合物、其制备方法及医药用途
TW202031644A (zh) 苯并咪唑衍生物
WO2005028453A1 (ja) フェニル酢酸誘導体、その製造方法および用途
KR20150082301A (ko) 2-피리돈 화합물
KR101835133B1 (ko) 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees